Best Hospitals for Dilation and Curettage (D&C) in Hyderabad, India

The total cost of a D&C procedure varies based on the surgical technique used, the hospital tier, anaesthesia type, and whether concurrent interventions such as hysteroscopic polypectomy or endometrial ablation are performed. In India, a straightforward D&C (MVA or sharp curettage under sedation or general anaesthesia at a NABH/JCI-accredited private hospital) costs approximately USD 400–900. A hysteroscopy-guided diagnostic and operative D&C — including surgeon fees, anaesthesia, operating theatre charges, one overnight stay if required, standard medications, post-operative TVUS, and pathology processing — typically costs USD 800–1,800 in India. In the UAE (Dubai or Abu Dhabi), the equivalent simple D&C costs approximately USD 900–1,500, while a full hysteroscopy-guided operative D&C at a JCI/DHA-accredited hospital costs USD 1,800–3,500. India is generally 40–60% more cost-effective than the UAE for the same procedure and accreditation standard. Importantly, neither destination's cost includes international airfare, post-operative hotel accommodation, or medications purchased locally; GAF Healthcare provides itemised cost estimates for the complete medical journey during the pre-arrival teleconsultation, allowing patients to plan accurately with no hidden charges.

D&C is primarily performed as a day-care (outpatient) procedure, and most patients are discharged 2–4 hours after the procedure with appropriate pain management and written discharge instructions. However, international travel — particularly long-haul flights — introduces specific considerations that make immediate post-procedure travel inadvisable. For short-haul flights (under 4 hours), gynaecologists at GAF Healthcare's partner hospitals typically clear patients to fly at 3–5 days post-procedure, provided that: vaginal bleeding has reduced to minimal spotting, the patient is afebrile (temperature <37.5°C), pain is controlled with oral analgesics, and there is no clinical or ultrasound evidence of incomplete evacuation or infection. For long-haul international flights (6 hours or more), the recommended minimum stay is 7–10 days. This extended period serves multiple purposes: it allows for receipt and review of histopathology results (typically available in 3–5 working days), ensures that any early complications such as retained products, endometritis, or abnormal bleeding are identified and managed before the patient is far from the treating centre, and reduces the theoretical thromboembolism risk associated with prolonged immobility during flight in the early post-operative period. A formal fit-to-fly letter is issued by the treating gynaecologist and provided to the patient by GAF Healthcare before airport departure. Patients with complicating factors — anaemia, ongoing bleeding, fever, or a concurrent procedure such as hysteroscopic myomectomy — may require an extended stay, which is communicated during the post-operative review.

D&C has an overall procedural success rate of 95–98% across its primary indications when performed by experienced gynaecologists at accredited facilities, which is the standard upheld at all GAF Healthcare partner hospitals in India and the UAE. Broken down by indication: for surgical management of incomplete or missed abortion using suction evacuation (MVA or EVA), complete evacuation rates are 98–99.5% at first attempt, with a re-intervention rate of less than 1.5%. For diagnostic D&C in abnormal uterine bleeding or postmenopausal bleeding, histopathological tissue adequacy (the ability to produce a reportable sample) exceeds 95% when performed under hysteroscopic guidance, compared to approximately 60–70% with traditional blind curettage — a clinically important distinction, as an inadequate sample may delay cancer diagnosis. For therapeutic hysteroscopy-guided D&C with concurrent polypectomy, complete polyp removal is achieved in 93–97% of cases at first procedure. When D&C is used as a component of endometrial ablation (NovaSure™ radiofrequency system), amenorrhoea rates at 12 months are 80–85%, with overall patient satisfaction rates exceeding 90%. The primary factors influencing success rate are: surgeon experience and case volume, use of hysteroscopic guidance (strongly recommended over blind curettage by ACOG and RCOG), adequacy of cervical preparation, and appropriate patient selection. GAF Healthcare's credentialing process verifies that all partner gynaecologists have a minimum annual case volume, fellowship training in operative gynaecology or minimally invasive surgery, and active hospital privileges at JCI- or NABH-accredited institutions.